Laquinimod, a new oral drug for multiple sclerosis

The Lancet

Volumn 371, Issue 9630, 2008, Pages 2059-2060

  Keegan, B Mark ^a   Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; PLACEBO; ROQUINIMEX;

ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 45249089662     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60894-6     Document Type: Note

References (17)

1. Noseworthy J., Lucchinetti C., Rodriguez M., and Weinshenker B. Multiple sclerosis. N Engl J Med 343 (2000) 938-952
2. Comi G., Pulizzi A., Rovaris M., et al., for the LAQ/5062 Study Group. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371 (2008) 2085-2092
3. Polman C., Barkhof F., Sandberg-Wollheim M., et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64 (2005) 987-991
4. van Waesberghe J., Castelijns J., Roser W., et al. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 18 (1997) 1279-1285
5. Kurtzke J. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
6. Cutter G., Baier M., Rudick R., et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122 (1999) 871-882
7. Miller D. MRI monitoring of MS in clinical trials. Clin Neurol Neurosurg 104 (2002) 236-243
8. van Walderveen M., Kamphorst W., Scheltens P., et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50 (1998) 1282-1288
9. Kappos L., Moeri D., Radue E., et al., for the Gadolinium MRI Meta-analysis Group. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 353 (1999) 964-969
10. Li D., Held U., Petkau J., et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66 (2006) 1384-1389
11. Fisniku L., Brex P., Altmann D., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131 (2008) 808-817
12. Truyen L., van Waesberghe J., van Walderveen M., et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47 (1996) 1469-1476
13. Comi G., Filippi M., Wolinsky J., and for the Group ECGAS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49 (2001) 290-297
14. Li D., and Paty D. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis: prevention of relapses and disability by interferon-beta 1a subcutaneously in multiple sclerosis. Ann Neurol 46 (1999) 197-206
15. Miller D., Soon D., Fernando K., et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68 (2007) 1390-1401
16. Noseworthy J., Wolinsky J., Lublin F., et al., for the North American Linomide Investigators. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. Neurology 54 (2000) 1726-1733
17. Berger J., and Koralnik I. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences. N Engl J Med 353 (2005) 414-416